Nondopaminergic neurotransmission in the pathophysiology of tourette syndrome

International Review of Neurobiology

Volumn 112, Issue , 2013, Pages 95-130

  Udvardi, Patrick T ^a   Nespoli, Ester ^a,b   Rizzo, Francesca ^a   Hengerer, Bastian ^b   Ludolph, Andrea G ^a  

^a UNIVERSITY OF ULM   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

GABA; Glutamate; Histamine; Nondopaminergic neurotransmission; Norepinephrine; Serotonin

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ACETYLCYSTEINE; ATOMOXETINE; BACLOFEN; BF 2649; CLONIDINE; CORTICOSTEROID; DONEPEZIL; DOPAMINE; DRONABINOL; ENDOCANNABINOID; FLUOXETINE; GALANTAMINE; GLUTAMIC ACID; GUANFACINE; HISTAMINE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORADRENALIN; ONDANSETRON; PAROXETINE; PITOLISANT; PLACEBO; PREDNISOLONE; RILUZOLE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIGABATRIN;

ARTICLE; ATTENTION DEFICIT DISORDER; AUTOPSY; CONTROLLED CLINICAL TRIAL (TOPIC); DOPAMINERGIC SYSTEM; DRUG WITHDRAWAL; GENE EXPRESSION; GENETIC ASSOCIATION; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HUMAN; NEUROIMAGING; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEDATION; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TIC; UNSPECIFIED SIDE EFFECT;

GABA; GLUTAMATE; HISTAMINE; NONDOPAMINERGIC NEUROTRANSMISSION; NOREPINEPHRINE; SEROTONIN;

ADRENAL CORTEX HORMONES; HUMANS; NEUROTRANSMITTER AGENTS; POSITRON-EMISSION TOMOGRAPHY; SYNAPTIC TRANSMISSION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOURETTE SYNDROME;

EID: 84888426884     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-411546-0.00004-4     Document Type: Chapter

References (124)

1. Adamczyk A., Gause C.D., Sattler R., Vidensky S., Rothstein J.D., Singer H., et al. Genetic and functional studies of a missense variant in a glutamate transporter, SLC1A3, in Tourette syndrome. Psychiatric Genetics 2011, 21(2):90-97.
2. Alcantara A.A., Chen V., Herring B.E., Mendenhall J.M., Berlanga M.L. Localization of dopamine D2 receptors on cholinergic interneurons of the dorsal striatum and nucleus accumbens of the rat. Brain Research 2003, 986(1-2):22-29.
3. Aliane V., Perez S., Bohren Y., Deniau J.M., Kemel M.L. Key role of striatal cholinergic interneurons in processes leading to arrest of motor stereotypies. Brain: A Journal of Neurology 2011, 134(Pt. 1):110-118.
4. Anderson G.M., Pollak E.S., Chatterjee D., Leckman J.F., Riddle M.A., Cohen D.J. Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome. Advances in Neurology 1992, 58:123-133.
5. Anderson G.M., Pollak E.S., Chatterjee D., Leckman J.F., Riddle M.A., Cohen D.J. Brain monoamines and amino acids in Gilles de la Tourette's syndrome: A preliminary study of subcortical regions. Archives of General Psychiatry 1992, 49(7):584-586.
6. Arnold P.D., Macmaster F.P., Richter M.A., Hanna G.L., Sicard T., Burroughs E., et al. Glutamate receptor gene (GRIN2B) associated with reduced anterior cingulate glutamatergic concentration in pediatric obsessive-compulsive disorder. Psychiatry Research 2009, 172(2):136-139.
7. Arnold P.D., Rosenberg D.R., Mundo E., Tharmalingam S., Kennedy J.L., Richter M.A. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: A preliminary study. Psychopharmacology 2004, 174(4):530-538.
8. Arnold P.D., Sicard T., Burroughs E., Richter M.A., Kennedy J.L. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Archives of General Psychiatry 2006, 63(7):769-776.
9. Barr C.L., Wigg K.G., Pakstis A.J., Kurlan R., Pauls D., Kidd K.K., et al. Genome scan for linkage to Gilles de la Tourette syndrome. American Journal of Medical Genetics 1999, 88(4):437-445.
10. Behen M., Chugani H.T., Juhasz C., Helder E., Ho A., Maqbool M., et al. Abnormal brain tryptophan metabolism and clinical correlates in Tourette syndrome. Movement Disorders: Official Journal of the Movement Disorder Society 2007, 22(15):2256-2262.
11. Berding G., Muller-Vahl K., Schneider U., Gielow P., Fitschen J., Stuhrmann M., et al. [123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Delta9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in Tourette patients. Biological Psychiatry 2004, 55(9):904-915.
12. Bredt D.S., Nicoll R.A. AMPA receptor trafficking at excitatory synapses. Neuron 2003, 40(2):361-379.
13. Bruun R.D., Budman C.L. Paroxetine treatment of episodic rages associated with Tourette's disorder. Journal of Clinical Psychiatry 1998, 59(11):581-584.
14. Buse J., Schoenefeld K., Münchau A., Roessner V. Neuromodulation in Tourette syndrome: Dopamine and beyond. Neuroscience and Biobehavioral Reviews 2013, 37(6):1069-1084.
15. Cath D.C., Ludolph A.G. Other psychiatric comorbidities in Tourette syndrome. Tourette Syndrome 2013, 74-106. Oxford University Press, New York. D. Martino, J.F. Leckman (Eds.).
16. Cavallini M.C., Di Bella D., Catalano M., Bellodi L. An association study between 5-HTTLPR polymorphism, COMT polymorphism, and Tourette's syndrome. Psychiatry Research 2000, 97(2-3):93-100.
17. Cavanna A.E., Selvini C., Termine C., Balottin U., Eddy C.M. Tolerability profile of clonidine in the treatment of adults with Tourette syndrome. Clinical Neuropharmacology 2012, 35(6):269-272.
18. Cerqueira J.J., Mailliet F., Almeida O.F.X., Jay T.M., Sousa N. The prefrontal cortex as a key target of the maladaptive response to stress. The Journal of Neuroscience 2007, 27:2781-2787.
19. Chakrabarty K., Bhattacharyya S., Christopher R., Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2005, 30(9):1735-1740.
20. Chappell P., Leckman J., Goodman W., Bissette G., Pauls D., Anderson G., et al. Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: Comparison to obsessive compulsive disorder and normal controls. Biological Psychiatry 1996, 39:776-783.
21. Chappell P., Riddle M., Anderson G., Scahill L., Hardin M., Walker D., et al. Enhanced stress responsivity of Tourette syndrome patients undergoing lumbar puncture. Biological Psychiatry 1994, 36(1):35-43.
22. Chen G., Trombley P.Q., van den Pol A.N. Excitatory actions of GABA in developing rat hypothalamic neurones. The Journal of Physiology 1996, 494(2):451-464.
23. 2+ of rat cerebellar granule cells in explant cultures. The Journal of neuroscience: The Official Journal of the Society for Neuroscience 1987, 7(5):1384-1400.
24. Corbett B.A., Mendoza S.P., Baym C.L., Bunge S.A., Levine S. Examining cortisol rhythmicity and responsivity to stress in children with Tourette syndrome. Psychoneuroendocrinology 2008, 33(6):810-820.
25. Coric V., Taskiran S., Pittenger C., Wasylink S., Mathalon D.H., Valentine G., et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. Biological Psychiatry 2005, 58(5):424-428.
26. Craig A.D. How do you feel? Interoception: The sense of the physiological condition of the body. Nature Reviews. Neuroscience 2002, 3(8):655-666.
27. Cubo E., Fernandez Jaen A., Moreno C., Anaya B., Gonzalez M., Kompoliti K. Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: An 18-week, single-center, dose-escalating, prospective, open-label study. Clinical Therapeutics 2008, 30(1):182-189.
28. Cull-Candy S., Brickley S., Farrant M. NMDA receptor subunits: Diversity, development and disease. Current Opinion in Neurobiology 2001, 11(3):327-335.
29. Curtis A., Clarke C.E., Rickards H.E. Cannabinoids for Tourette's syndrome. The Cochrane Database of Systematic Reviews 2009, (4). CD006565. 10.1002/146511858.CD006565.
30. Davies J., Evans R.H., Francis A.A., Watkins J.C. Excitatory amino acid receptors and synaptic excitation in the mammalian central nervous system. Journal de physiologie 1979, 75(6):641-654.
31. Dehning S., Muller N., Matz J., Bender A., Kerle I., Benninghoff J., et al. A genetic variant of HTR2C may play a role in the manifestation of Tourette syndrome. Psychiatric Genetics 2010, 20(1):35-38.
32. Dickel D.E., Veenstra-VanderWeele J., Cox N.J., Wu X., Fischer D.J., Van Etten-Lee M., et al. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Archives of General Psychiatry 2006, 63(7):778-785.
33. Dietl T., Kümpfel T., Hinze-Selch D., Trenkwalder C., Lechner C. Exacerbation of tics by prednisolone. Nervenarzt 1998, 69(12):1111-1114.
34. Ding Y.S., Lin K.S., Logan J. PET imaging of norepinephrine transporters. Current Pharmacological Design 2006, 12(30):3831-3845.
35. Eapen V., Trimble M.R., Robertson M.M. The use of fluoxetine in Gilles de la Tourette syndrome and obsessive compulsive behaviours: Preliminary clinical experience. Progress in Neuro-Psychopharmacology & Biological Psychiatry 1996, 20(4):737-743.
36. Ellender T.J., Huerta-Ocampo I., Deisseroth K., Capogna M., Bolam J.P. Differential modulation of excitatory and inhibitory striatal synaptic transmission by histamine. The Journal of Neuroscience 2011, 31:15340-15351.
37. Ercan-Sencicek A.G., Stillman A.A., Ghosh A.K., Bilguvar K., O'Roak B.J., Mason C.E., et al. L-histidine decarboxylase and Tourette's syndrome. The New England Journal of Medicine 2010, 362(20):1901-1908.
38. Erickson K., Drevets W., Schulkin J. Glucocorticoid regulation of diverse cognitive functions in normal and pathological emotional states. Neuroscience and Biobehavioral Reviews 2003, 3:233-246.
39. Felling R.J., Singer H.S. Neurobiology of Tourette syndrome: Current status and need for further investigation. The Journal of Neuroscience 2011, 31(35):12387-12395.
40. Fernandez T.V., Sanders S.J., Yurkiewicz I.R., Ercan-Sencicek A.G., Kim Y.S., Fishman D.O., et al. Rare copy number variants in Tourette syndrome disrupt genes in histaminergic pathways and overlap with autism. Biological Psychiatry 2012, 71(5):392-402.
41. Ferreira P.E.M.S., Palmini A., Bau C.H.D., Grevet E.H., Hoefel J.R., Rohde L.A., et al. Differentiating attention-deficit/hyperactivity disorder inattentive and combined types: A (1)H-magnetic resonance spectroscopy study of fronto-striato-thalamic regions. Journal of neural transmission (Vienna, Austria: 1996) 2009, 116(5):623-629.
42. Findley D.B., Leckman J.F., Katsovich L., et al. Development of the Yale children's global stress index (YCGSI) and its application in children and adolescents with Tourette syndrome and obsessive-compulsive disorder. Journal of American Academy of Child and, Adolescent Psychiatry 2003, 42(4):450-457.
43. Freeman R.D., Fast D.K., Burd L., Kerbeshian J., Robertson M.M., Sandor P. An international perspective on Tourette syndrome: Selected findings from 3500 individuals in 22 countries. Developmental Medicine & Child Neurology 2000, 42:436-447.
44. Gadzicki D., Muller-Vahl K.R., Heller D., Ossege S., Nothen M.M., Hebebrand J., et al. Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene. American Journal of Medical Genetics Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics 2004, 127B(1):97-103.
45. Gilbert D.L., Christian B.T., Gelfand M.J., Shi B., Mantil J., Sallee F.R. Altered mesolimbocortical and thalamic dopamine in Tourette syndrome. Neurology 2006, 67(9):1695-1697.
46. Groeneweg F.L., Karst H., de Kloet E.R., Joels M. Rapid non-genomic effects of corticosteroids and their role in the central stress response. Journal of Endocrinology 2011, 209:153-167.
47. Haller J., Mikics E., Makara G.B. The effects of non-genomic glucocorticoid mechanisms on bodily functions and the central neural system. A critical evaluation of findings. Frontiers in Neuroendocrinology 2008, 29(2):273-291.
48. Handley S.H., Dursun S.M. Serotonin and Tourette's syndrome: Movements such as head-shakes and wet-dog shakes may model human tics. Advances in the Biosciences 1993, 85:235-253.
49. Hardingham G.E., Fukunaga Y., Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nature Neuroscience 2002, 5(5):405-414.
50. Harris K., Singer H.S. Tic disorders: Neural circuits, neurochemistry, and neuroimmunology. Journal of Child Neurology 2006, 21(8):678-689.
51. Hartmann A., Worbe Y., Arnulf I. Increasing histamine neurotransmission in Gilles de la Tourette syndrome. Journal of Neurology 2012, 259(2):375-376.
52. Haugbøl S., Pinborg L.H., Regeur L., Hansen E.S., Bolwig T.G., Nielsen F.A., et al. Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome. The International Journal of Neuropsychopharmacology 2007, 2:245-252.
53. Hauser R.A., Zesiewicz T.A. Sertraline-induced exacerbation of tics in Tourette's syndrome. Movement Disorder 1995, 10(5):682-684.
54. Hayslett R.L., Tizabi Y. Effects of donepezil on DOI-induced head twitch response in mice: Implications for Tourette syndrome. Pharmacology, Biochemistry, and Behavior 2003, 76(3-4):409-415.
55. Heinz A., Knable M.B., Wolf S.S., Jones D.W., Gorey J.G., Hyde T.M., et al. Tourette's syndrome: [I-123]beta-CIT SPECT correlates of vocal tic severity. Neurology Journal 1998, 51(4):1069-1074.
56. Hill M.N., Tasker J.G. Endocannabinoid signaling, glucocorticoid-mediated negative feedback and regulation of the HPA axis. Neuroscience 2012, 204:5-16.
57. 18F]nifene PET in the nonhuman primate. Journal of Cerebral Blood Flow Metabolism 2013.
58. Hoekstra P.J., Dietrich A., Edwards M.J., Elamin I., Martino D. Environmental factors in Tourette syndrome. Neuroscience and Biobehavioral Reviews 2013, 37(6):1040-1049.
59. Joëls M., Baram T.Z. The neuro-symphony of stress. Nature Reviews. Neuroscience 2009, 10(6):459-466.
60. Jucaite A., Takano A., Boström E., Jostell K.G., Stenkrona P., Halldin C., et al. AZD5213: A novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects. The International Journal of Neuropsychopharmacology 2013, 6:1231-1239.
61. Kalanithi P.S.A., Zheng W., Kataoka Y., DiFiglia M., Grantz H., Saper C.B., et al. Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(37):13307-13312.
62. Kalisman N., Silberberg G., Markram H. The neocortical microcircuit as a tabula rasa. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(3):880-885.
63. Karagiannidis I., Dehning S., Sandor P., Tarnok Z., Rizzo R., Wolanczyk T., et al. Support of the histaminergic hypothesis in Tourette syndrome: Association of the histamine decarboxylase gene in a large sample of families. Journal of Medical Genetics 2013.
64. Kataoka Y., Kalanithi P.S., Grantz H., Schwartz M.L., Saper C., Leckman J.F., et al. Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome. The Journal of Comparative Neurology 2010, 518(3):277-291.
65. Kim J.J., Foy M.R., Thompson R.F. Behavioral stress modifies hippocampal plasticity through N-methyl-d-aspartate receptor activation. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:4750-4753.
66. Kondo K., Kabasawa T. Improvement in Gilles de la Tourette syndrome after corticosteroid therapy. Annals of Neurology 1978, 4(4):387.
67. Lau C.G., Zukin R.S. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nature Reviews. Neuroscience 2007, 8(6):413-426. 10.1038/nrn2153.
68. Leckman J.F., Ort S., Caruso K.A., Anderson G.M., Riddle M.A., Cohen D.J. Rebound phenomena in Tourette's syndrome after abrupt withdrawal of clonidine. behavioral, cardiovascular, and neurochemical effects. Archives of General Psychiatry 1986, 43(12):1168-1176.
69. Lerner A., Bagic A., Simmons J.M., Mari Z., Bonne O., Xu B., et al. Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome. Brain: A Journal of Neurology 2012, 135(Pt. 6):1926-1936.
70. Liao I.H., Corbett B.A., Gilbert D.L., Bunge S.A., Sharp F.R. Blood gene expression correlated with tic severity in medicated and unmedicated patients with Tourette syndrome. Pharmacogenomics 2010, 12:1733-1741.
71. Lin H., Katsovich L., Ghebremichael M., Findley D.B., Grantz H., Lombroso P.J., et al. Psychosocial stress predicts future symptom severities in children and adolescents with Tourette syndrome and/or obsessive-compulsive disorder. The Journal of Child Psychology and Psychiatry 2007, 48(2):157-166.
72. Lucas-Meunier E., Fossier P., Baux G., Amar M. Cholinergic modulation of the cortical neuronal network. Pflügers Archiv / European Journal of Physiology 2003, 446(1):17-29.
73. 18F]fluorophenyl-l-alanine PET study. NeuroImage 2008, 41(3):718-727.
74. Ludolph A.G., Roessner V., Münchau A., Müller-Vahl K. Tourette syndrome and other tic disorders in childhood, adolescence and adulthood. Deutsches Ärzteblatt International 2012, 109(48):821.
75. March J.S., Franklin M.E., Leonard H., Garcia A., Moore P., Freeman J., et al. Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder. Biological Psychiatry 2007, 61(3):344-347.
76. Monyer H., Burnashev N., Laurie D.J., Sakmann B., Seeburg P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994, 12(3):529-540.
77. Muller-Vahl K.R., Kolbe H., Dengler R. Gilles de la Tourette syndrome. Effect of nicotine, alcohol and marihuana on clinical symptoms. Der Nervenarzt 1997, 68(12):985-989. [Gilles de la Tourette-Syndrom. Einfluss von Nikotin, Alkohol und Marihuana auf die klinische Symptomatik].
78. Muller-Vahl K.R., Kolbe H., Schneider U., Emrich H.M. Cannabinoids: Possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatrica Scandinavica 1998, 98(6):502-506.
79. Muller-Vahl K.R., Schneider U., Koblenz A., Jöbges M., Kolbe H., Daldrup T., Emrich H.M. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002, 35(2):57-61.
80. Muller-Vahl K.R., Meyer G.J., Knapp W.H., Emrich H.M., Gielow P., Brucke T., et al. Serotonin transporter binding in Tourette syndrome. Neuroscience Letters 2005, 385(2):120-125.
81. Muller-Vahl K.R., Schneider U., Prevedel H., Theloe K., Kolbe H., Daldrup T., et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial. The Journal of Clinical Psychiatry 2003, 64(4):459-465.
82. Neuner I., Ludolph A. Tics and Tourette's syndrome throughout the life span. Der Nervenarzt 2009, 80(11):1377-1387.
83. Neuner I., Ludolph A.G. Neurobiology, clinical characteristics and therapy in Tourette's syndrome. Fortschritte der Neurologie Psychiatrie 2011, 79(12):724-732.
84. Niesler B., Frank B., Hebebrand J., Rappold G. Serotonin receptor genes HTR3A and HTR3B are not involved in gilles de la Tourette syndrome. Psychiatric Genetics 2005, 15(4):303-304.
85. Ogawa M., Tsukada H., Hatano K., Ouchi Y., Saji H., Magata Y. Central in vivo nicotinic acetylcholine receptor imaging agents for positron emission tomography (PET) and single photon emission computed tomography (SPECT). Biological Pharmaceutical Bulletin 2009, 32(3):337-340.
86. Oswald L.M., Wong D.F., McCaul M., Zhou Y., Kuwabara H., Choi L., et al. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology 2005, 30(4):821-832.
87. Ozbay F., Wigg K.G., Turanli E.T., Asherson P., Yazgan Y., Sandor P., et al. Analysis of the dopamine beta hydroxylase gene in Gilles de la Tourette syndrome. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2006, 141B(6):673-677.
88. Panula P., Nuutinen S. The histaminergic network in the brain: Basic organization and role in disease. Nature Review Neuroscience 2013, 14(7):472-487.
89. Paoletti P., Bellone C., Zhou Q. NMDA receptor subunit diversity: Impact on receptor properties, synaptic plasticity and disease. Nature Reviews. Neuroscience 2013, 14(6):383-400. 10.1038/nrn3504.
90. Popielarska A., Kuligowska M., Mazur M. On Gilles de la Tourette syndrome and therapeutic trials in the light of our observations. Pediatria Polska 1972, 47:1097-1103.
91. Popoli M., Yan Z., McEwen B.S., Sanacora G. The stressed synapse: The impact of stress and glucocorticoids on glutamate transmission. Nature Review Neuroscience 2011, 13(1):22-37. 10.1038/nrn3138.
92. Pringsheim T., Doja A., Gorman D., McKinlay D., Day L., Billinghurst L., et al. Canadian guidelines for the evidence-based treatment of tic disorders: Pharmacotherapy. Canadian Journal of Psychiatry 2012, 57(3):133-143.
93. Rickards H. Functional neuroimaging in Tourette syndrome. Journal of Psychosomatic Research 2009, 67(6):575-584.
94. Rickards H., Hartley N., Robertson M.M. Seignot's paper on the treatment of Tourette's syndrome with haloperidol. Classic text no. 31. History of Psychiatry 1997, 8(31 Pt. 3):433-436.
95. Roessner V., Plessen K.J., Rothenberger A., Ludolph A.G., Rizzo R., Skov L., et al. ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: Pharmacological treatment. European Child & Adolescent Psychiatry 2011, 20(4):173-196.
96. Sallee F.R., Richman H., Beach K., Sethuraman G., Nesbitt L. Platelet serotonin transporter in children and adolescents with obsessive-compulsive disorder or Tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry 1996, 35(12):1647-1656.
97. Sandyk R. Cholinergic mechanisms in gilles de la Tourette's syndrome. The International Journal of Neuroscience 1995, 81(1-2):95-100.
98. Saporta A.S., Chugani H.T., Juhasz C., Makki M.I., Muzik O., Wilson B.J., et al. Multimodality neuroimaging in Tourette syndrome: Alpha-[11C] methyl-L-tryptophan positron emission tomography and diffusion tensor imaging studies. Journal of Child Neurology 2010, 25(3):336-342.
99. Scahill L. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs 2009, 23(Suppl. 1):43-49.
100. Scahill L., Riddle M.A., King R.A., Hardin M.T., Rasmusson A., Makuch R.W., et al. Fluoxetine has no marked effect on tic symptoms in patients with Tourette's syndrome: A double-blind placebo-controlled study. Journal of Child and Adolescent Psychopharmacology 1997, 7(2):75-85.
101. Schmahmann J.D. Disorders of the cerebellum: Ataxia, dysmetria of thought, and the cerebellar cognitive affective syndrome. The Journal of Neuropsychiatry and Clinical Neurosciences 2004, 16(3):367-378.
102. Shafii M. The effects of sympathomimetic and antihistaminic agents on chronic motor tics and Tourette's disorder. New England Journal of Medicine 1986, 315(19):1228-1229.
103. Shapiro A.K., Shapiro E. Treatment of Gilles de la Tourette's syndrome with haloperidol. British Journal of Psychiatry 1968, 114(508):345-350.
104. Silva R.R., Munoz D.M., Barickman J.F., et al. Environmental factors and realted fluctuation of symptoms in children and adolescents with Tourette's disorder. The Journal of Child Psychology and Psychiatry 1995, 36:305-312.
105. Silvestri R., Raffaele M., De Domenico P., Tisano A., Laganà A., Di Perri R. Serotoninergic agents in the treatment of Gilles de la Tourette's syndrome. Acta Neurologica (Napoli) 1994, 16(1-2):58-63.
106. Singer H.S., Morris C., Grados M. Glutamatergic modulatory therapy for Tourette syndrome. Medical Hypotheses 2010, 74(5):862-867.
107. Singer H.S., Wendlandt J., Krieger M., Giuliano J. Baclofen treatment in Tourette syndrome: A double-blind, placebo-controlled, crossover trial. Neurology 2001, 56:599-604.
108. Smith S.M., Vale W.W. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues in Clinical Neuroscience 2006, 8(4):383-395.
109. Sousa N., Cerqueira J.J., Almeida O.F.X. Corticosteroid receptors and neuroplasticity. Brain Research Reviews 2008, 57(2):561-570.
110. Stahl S.M. Stahl's essential psychopharmacology 2009, Cambridge University Press, Chapter 16. 3rd ed.
111. Swerdlow N.R., Sutherland A.N. Using animal models to develop therapeutics for Tourette syndrome. Pharmacology & Therapeutics 2005, 108(3):281-293. 10.1016/j.pharmthera.2005.05.003.
112. Tashiro M., Duan X., Kato M., Miyake M., Watanuki S., Ishikawa Y., et al. Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin. British Journal of Clinical Pharmacology 2008, 65(6):811-821.
113. Threlfell S., Lalic T., Platt N.J., Jennings K.A., Deisseroth K., Cragg S.J. Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. Neuron 2012, 75(1):58-64.
114. Tian Y., Gunther J.R., Liao I.H., Liu D., Ander B.P., Stamova B.S., et al. GABA- and acetylcholine-related gene expression in blood correlate with tic severity and microarray evidence for alternative splicing in Tourette syndrome: A pilot study. Brain Research 2011, 1381:228-236.
115. Tinaz S., van der Veen J.W., Belluscio B.A., Popli K., Hallett M., Horovitz S. Reduced GABA in the sensorimotor cortex (SMC) of patients with Tourette syndrome (TS) as measured by H-magnetic resonance spectroscopy (MRS) [abstract]. Movement Disorders 2012, 27(Suppl. 1):1341.
116. Toren P., Weizman A., Ratner S., Cohen D., Laor N. Ondansetron treatment in Tourette's disorder: A 3-week, randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry 2005, 66(4):499-503.
117. TSAICG Genome scan for Tourette disorder in affected-sibling-pair and multigenerational families. American Journal of Human Genetics 2007, 80(2):265-272.
118. Tsigos C., Chrousos G.P. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. Journal of Psychosomatic Research 2002, 53:865-871.
119. Tuomisto L., Panula P. Development of histaminergic neurons. Histaminergic neurons: Morphology and function 1991, 177-192. CRC Press, Boca Raton, Ann Arbor, Boston. T. Watanabe, H. Wada (Eds.).
120. Van Ruitenbeek P., Mehta M.A. Potential enhancing effects of histamine H1 agonism/H3 antagonism on working memory assessed by performance and bold response in healthy volunteers. British Journal of Pharmacology 2013, 170(1):144-155.
121. Weeks R.A., Lees A.J., Brooks D.J. Tourette's syndrome and the opioid system. The Lancet 1994, 343(8905):1107-1108.
122. Wong D.F., Brasić J.R., Singer H.S., Schretlen D.J., Kuwabara H., Zhou Y., et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: Clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology 2008, 33(6):1239-1251.
123. Ye J.H., Ponnudurai R., Schaefer R. Ondansetron: A selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. CNS Drug Reviews 2001, 7(2):199-213.
124. Yin L., Zhao Q., Li L., Zhang S.L., Chen X.Q., Ma C., et al. An experimental study on (131)I-CHIBA-1001: A radioligand for α7 nicotinic acetylcholine receptors. PLoS One 2013, 8(7):e70188. 10.1371/journal.pone.0070188.